Lorena Rami1, Maria A Mollica2, Carmen García-Sanchez3, Judith Saldaña4, Belen Sanchez3, Isabel Sala3, Cinta Valls-Pedret5, Magda Castellví1, Jaume Olives2, Jose L Molinuevo1. 1. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 2. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain. 3. Memory Unit. Neurology Service. Hospital Santa Creu i Sant Pau, Barcelona, Spain. 4. Hospital de Mollet del Vallés, Barcelona, Spain. 5. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona, Spain.
Abstract
BACKGROUND: Subjective cognitive decline (SCD) is gaining importance as a focus of investigation, but adequate tools are needed for its quantification. OBJECTIVE: To develop and validate a questionnaire to quantify SCD, termed the Subjective Cognitive Decline Questionnaire (SCD-Q). METHODS: 124 controls (CTR), 144 individuals with SCD, 83 mild cognitive impairment subjects, 46 Alzheimer's disease patients, and 397 informants were included. The SCD-Q contains: part I, named MyCog, which is answered by the subject; and part II, TheirCog, which includes the same questions and is answered by the informant or caregiver. The 24 SCD-Q items assess the perceived subjective decline in memory, language, and executive functions in the last two years. RESULTS: The MyCog scores of controls differed significantly from those of the other groups (p < 0.05) and there were significant differences in TheirCog scores between all groups. The optimal TheirCog cut-off score for discriminating between individuals with and without cognitive impairment was 7/24 (sensitivity 85%, specificity 80%). MyCog scores correlated significantly with anxiety and depression (r = 0.29, r = 0.43, p < 0.005), but no correlations were found with neuropsychological tests. TheirCog scores correlated significantly with most of the neuropsychological tests (p < 0.05). Informants' depression and anxiety influenced TheirCog scores in controls and SCD groups. CONCLUSION: Self-perceived cognitive decline, measured by the SCD-Q part I (MyCog), discriminated SCD from CTR. Part II (TheirCog) was strongly related to subjects' objective cognitive performance, and discriminated between subjects with or without cognitive impairment. The SCD-Q is a useful tool to measure self-perceived cognitive decline incorporating the decliner and the informant perspective.
BACKGROUND: Subjective cognitive decline (SCD) is gaining importance as a focus of investigation, but adequate tools are needed for its quantification. OBJECTIVE: To develop and validate a questionnaire to quantify SCD, termed the Subjective Cognitive Decline Questionnaire (SCD-Q). METHODS: 124 controls (CTR), 144 individuals with SCD, 83 mild cognitive impairment subjects, 46 Alzheimer's diseasepatients, and 397 informants were included. The SCD-Q contains: part I, named MyCog, which is answered by the subject; and part II, TheirCog, which includes the same questions and is answered by the informant or caregiver. The 24 SCD-Q items assess the perceived subjective decline in memory, language, and executive functions in the last two years. RESULTS: The MyCog scores of controls differed significantly from those of the other groups (p < 0.05) and there were significant differences in TheirCog scores between all groups. The optimal TheirCog cut-off score for discriminating between individuals with and without cognitive impairment was 7/24 (sensitivity 85%, specificity 80%). MyCog scores correlated significantly with anxiety and depression (r = 0.29, r = 0.43, p < 0.005), but no correlations were found with neuropsychological tests. TheirCog scores correlated significantly with most of the neuropsychological tests (p < 0.05). Informants' depression and anxiety influenced TheirCog scores in controls and SCD groups. CONCLUSION: Self-perceived cognitive decline, measured by the SCD-Q part I (MyCog), discriminated SCD from CTR. Part II (TheirCog) was strongly related to subjects' objective cognitive performance, and discriminated between subjects with or without cognitive impairment. The SCD-Q is a useful tool to measure self-perceived cognitive decline incorporating the decliner and the informant perspective.
Entities:
Keywords:
Alzheimer's disease; cognition; diagnosis; memory; test
Authors: Laura A Rabin; Colette M Smart; Paul K Crane; Rebecca E Amariglio; Lorin M Berman; Mercé Boada; Rachel F Buckley; Gaël Chételat; Bruno Dubois; Kathryn A Ellis; Katherine A Gifford; Angela L Jefferson; Frank Jessen; Mindy J Katz; Richard B Lipton; Tobias Luck; Paul Maruff; Michelle M Mielke; José Luis Molinuevo; Farnia Naeem; Audrey Perrotin; Ronald C Petersen; Lorena Rami; Barry Reisberg; Dorene M Rentz; Steffi G Riedel-Heller; Shannon L Risacher; Octavio Rodriguez; Perminder S Sachdev; Andrew J Saykin; Melissa J Slavin; Beth E Snitz; Reisa A Sperling; Caroline Tandetnik; Wiesje M van der Flier; Michael Wagner; Steffen Wolfsgruber; Sietske A M Sikkes Journal: J Alzheimers Dis Date: 2015-09-24 Impact factor: 4.472
Authors: Chatchawan Rattanabannakit; Shannon L Risacher; Sujuan Gao; Kathleen A Lane; Steven A Brown; Brenna C McDonald; Frederick W Unverzagt; Liana G Apostolova; Andrew J Saykin; Martin R Farlow Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Mariella Lauriola; Roberto Esposito; Stefano Delli Pizzi; Massimiliano de Zambotti; Francesco Londrillo; Joel H Kramer; Gil D Rabinovici; Armando Tartaro Journal: Alzheimers Dement Date: 2016-12-27 Impact factor: 21.566
Authors: Nikki L Hill; Jacqueline Mogle; Rachel Wion; Elizabeth Munoz; Nicole DePasquale; Andrea M Yevchak; Jeanine M Parisi Journal: Gerontologist Date: 2016-06-23
Authors: José L Molinuevo; Laura A Rabin; Rebecca Amariglio; Rachel Buckley; Bruno Dubois; Kathryn A Ellis; Michael Ewers; Harald Hampel; Stefan Klöppel; Lorena Rami; Barry Reisberg; Andrew J Saykin; Sietske Sikkes; Colette M Smart; Beth E Snitz; Reisa Sperling; Wiesje M van der Flier; Michael Wagner; Frank Jessen Journal: Alzheimers Dement Date: 2016-11-05 Impact factor: 21.566
Authors: Frank Jessen; Rebecca E Amariglio; Rachel F Buckley; Wiesje M van der Flier; Ying Han; José Luis Molinuevo; Laura Rabin; Dorene M Rentz; Octavio Rodriguez-Gomez; Andrew J Saykin; Sietske A M Sikkes; Colette M Smart; Steffen Wolfsgruber; Michael Wagner Journal: Lancet Neurol Date: 2020-01-17 Impact factor: 44.182
Authors: Laura A Rabin; Crystal G Guayara-Quinn; Caroline O Nester; Liam Ellis; Nadia Paré Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2021-02-23